Document is current

Article History

Received: 3 March 2022

Accepted: 15 November 2022

First Online: 12 December 2022

Declarations

:

: The trial protocol is in accordance with the principles of the Declaration of Helsinki and has been approved by the ethics committee of the University Hospital Lübeck on 19 January 2021 (20-285). This trial was registered at the German Registry of Clinical Studies (Deutsches Register Klinischer Studien), DRKS-ID: DRKS00024657, registered on March 8, 2021. Each participant will be informed regarding the study protocol, and written informed consent will be obtained from each participant. The study site led by the principal investigator is responsible for collecting the informed consent. This is independently monitored by the ZKS.

: Not applicable

: TS and GK are both employed at Perfood GmbH. TS and CS are co-founders of Perfood GmbH and minority shareholders. D.T.: consulting fees from Perfood; research support/principal investigator (clinical trials): AbbVie, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, Dermira, Eli Lilly, Galderma, GSK, Janssen-Cilag, Leo-Pharma, Novartis, Pfizer, Regeneron, Roche, Sandoz-Hexal, Sanofi, and UCB; consultant: AbbVie, Almirall, Amgen, Dignity, Galapagos, Leo Pharma, Maruho, Mitsubishi, Novartis, Sanofi, Pfizer, Regeneron, Target-Solution, and UCB ; lectures: AbbVie, Almirall, Amgen, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Roche-Posay, Sandoz-Hexal, Sanofi, and UCB; scientific advisory board: AbbVie, Boehringer Ingelheim, Eli Lilly, Galapagos, Janssen-Cilag, Leo Pharma, Morphosis, Novartis, Pfizer, Regeneron, Sanofi, and UCB.The views presented in this manuscript are those of the authors and not necessarily those of Perfood GmbH. Good publication practices were followed.